TriVascular Technologies, Inc. (TRIV)

[PerserNL]

TRIV huge potential and price-target +100%, read this:


Stock Price Target

Sell-side firms covering the company, have a 12-month price target of $10.333 on the stock. This is according to the 3 analysts polled by Zacks which are taken into account to arrive at the average. The most positive analyst view sees the stock reaching $13. On the other hand, the most conservative analyst report has a $9 price target on the name.

Zacks compiles analyst recommendations into a simplified scale due to the complexity of the various methods and terminology of research firms. The scale provides an Average Broker Rating based on a 1 to 5 sliding scale where 1 signifies a Strong Buy and 5 a Strong Sell recommendation. TriVascular Technologies, Inc. currently has an average broker rating of 1. The stock had a rating of 1 three months ago.

http://www.investornewswire.com/analyst-views/quarterly-earnings-watch-trivascular-technologies-inc-nasdaqtriv/44790/

[PerserNL]

Watch TRIV price-target +100% by analysts:

http://theenterpriseleader.com/stock-watch/growth-stock-watch-trivascular-technologies-inc-nasdaqtriv-3/25102/

TriVascular Technologies, Inc. (NASDAQ:TRIV) has been given a positive Growth Style Score by Zacks Research. The Growth score analyzes the growth prospects for a company in addition to analyzing company financials. The score takes into account various measures of the Income Statement, Cash Flow Statement and Balance Sheet to achieve a ranking of A-F, where A indicates that the stock has the best growth characteristics likely to outperform the market.

[PerserNL]

Huge potential for TRIV, will double according to analysts:

A number of equities research analysts recently issued reports on the stock. Bank of America initiated coverage on shares of Trivascular Technologies in a research report on Thursday, July 9th. They issued a “buy” rating on the stock. Credit Suisse reissued a “hold” rating and set a $8.00 price target (down previously from $10.00) on shares of Trivascular Technologies in a research report on Monday, August 10th. Canaccord Genuity reaffirmed a “buy” rating and issued a $13.00 target price on shares of Trivascular Technologies in a report on Wednesday, August 5th. BTIG Research reiterated a “buy” rating and issued a $8.00 price target on shares of Trivascular Technologies in a research note on Wednesday, August 5th. Finally, Zacks upgraded shares of Trivascular Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, July 7th.

Read more: http://www.financialwisdomworks.com/brokerages-set-trivascular-technologies-price-target-at-9-80-nasdaqtriv/24009/

[PerserNL]

TRIV +100%-price-target by analysts:


Stock Targets

Wall Street analysts covering the stock, on a consensus basis, have a one-year price target of $10.333 on the equity. This is based on the 3 individual recommendations by the firms tracked by Zacks. The most aggressive target sees the stock headed to $13 while the most bearish has a $9 target. Zacks also uses a method in order to simplify the various recommendations into a 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell. Shares of TriVascular Technologies, Inc. currently have an average broker rating of 1. Three months ago when the same analysts were polled, the ABR was at 1

http://www.investornewswire.com/analyst-views/can-trivascular-technologies-inc-nasdaqtriv-post-an-earnings-surprise-this-quarter/39182/

[PerserNL]

News today, TRIV is getting on the radar, low float so this news already made a gain of 12.7%.

http://www.nasdaq.com/press-release/trivascular-technologies-inc-announces-first-patients-treated-in-europe-with-ovation-ixtm-abdomina-20150915-01106

[dayneyus]

Life Study Press release Aug 3 2015

TriVascular Reaches Major Milestones in Key Clinical Studies

Growing Body of Evidence Supports the Strong Safety, Effectiveness and Clinical Utility of the Ultra-Low Profile Ovation(R) System

SANTA ROSA, Calif., Aug. 3, 2015 (GLOBE NEWSWIRE) -- TriVascular Technologies, Inc. (NASDAQ:TRIV), manufacturer of the Ovation Abdominal Stent Graft platform, announced today two major clinical milestones: surpassing 100 patients enrolled in the Least Invasive Fast-Track EVAR (LIFE) study and completion of patient enrollment in the U.S. Post Approval Study. These achievements demonstrate the Company's ongoing commitment to significantly advance endovascular aortic repair (EVAR) of abdominal aortic aneurysms.

The LIFE study is designed to evaluate clinical outcomes and healthcare economic data on patients treated with the Ovation system utilizing the Fast-Track treatment protocol. Under Fast-Track, vessel access is gained via a bilateral percutaneous approach, local or regional anesthesia is utilized, ICU admission post-procedure is avoided and the patient is discharged the following day. This patient-friendly, resource-efficient treatment pathway is enabled by the Ovation system and has the potential to meaningfully improve the practice of EVAR. The LIFE Study is led by co-national principal investigators Zvonimir Krajcer, MD, FACC, Co-Director, Peripheral Vascular Disease Service at Texas Heart Institute in Houston, Texas and Venkatesh G. Ramaiah, MD, FACS, Director of Research at the Arizona Heart Institute and Medical Director of the Arizona Heart Hospital in Phoenix, Arizona.

"The Ovation system's low profile, and proven clinical value, when combined with less invasive percutaneous access and the potential to avoid general anesthesia, should yield excellent patient outcomes with lower costs, shorter procedures and high patient satisfaction," said Dr. Krajcer. "Dr. Ramaiah and I are excited to partner with TriVascular on this important registry. The results of the LIFE study will significantly contribute to the existing literature and add momentum to the inevitable transition toward a fast-track, next-day discharge EVAR protocol."

TriVascular also announced today the completion of the U.S. Post Approval Study (PAS). The PAS is a prospective, multi-center study that further evaluates the safety and effectiveness of the Ovation platform in a real world clinical setting. This study augments the Ovation global pivotal trial cohort as outlined in the conditions of the premarket approval application (PMA) with subjects followed for up to five years, per the required study timeline.

"By a considerable margin, the Ovation system has the broadest indications for use of any system and, as a result, has allowed us to treat patients that are otherwise ineligible for an on-label EVAR solution," commented Syed Hussain, MD, the PAS national principal investigator, Chairman of Vascular and Endovascular Surgery at Christie Clinic and Assistant Professor of Surgery at the University of Illinois. "We are excited to have partnered with TriVascular on this important study. The ongoing results of the study will further expand the clinical evidence demonstrating the safety and effectiveness profile of the Ovation system. In our practice, the Ovation system is our frontline device."

"We are focused on developing products and providing clinical evidence to help expand EVAR access to more patients and improve EVAR outcomes for all patients," said Christopher G. Chavez, Chairman, CEO and President of TriVascular. "We are excited to have reached these major clinical milestones and are grateful to all of the study investigators who put their trust in our technology when caring for their patients."

The Ovation platform has been used in the successful treatment of over 7,000 patients worldwide. Excellent clinical results have been reported from both the Ovation global pivotal trial and a 501-patient European Post-Market Registry. The Ovation platform is available for sale in over 35 countries.

About TriVascular Technologies, Inc. - TriVascular is a medical device company developing and commercializing innovative technologies to significantly advance minimally invasive treatment of abdominal aortic aneurysms. The company manufactures the Ovation Abdominal Stent Graft platform, the lowest profile FDA-approved EVAR system, which utilizes a novel, polymer-based sealing mechanism. TriVascular is based in Santa Rosa, California.

Forward-Looking Statements

In addition to the historical information, this press release contains forward-looking statements with respect to our business, the Ovation system, our stent graft technology and our ability to expand EVAR treatment option to a broader population of patients with AAA disease. These forward-looking statements are based upon information that is currently available to us or our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including our ability to successfully commercialize our products; continued market acceptance of our endovascular aortic repair systems; our ability to manufacture our endovascular systems to meet demand; the level and availability of third party payor reimbursement for our products, our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; our ability to develop new or complementary technologies; the regulatory requirements applicable to us and our competitors; competition in our industry; additional capital and credit availability, our ability to attract and retain qualified personnel; product liability claims; and general economic and worldwide business conditions. These factors, together with those that are described in greater detail in our Annual Report on Form 10-K filed with the SEC on March 9, 2015 and our other filings with the SEC, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

[dayneyus]

Q2 out... seems they have gotten more normalized sales the real traction will come after there sales force is all filled out. looks like next year?
Next catalyst will be some on going clinical Life studies that are gathering data for presentation at up coming events.
http://investors.trivascular.com/eventdetail.cfm?EventID=162008

[dayneyus]

Placed alerts of $6.84 high side and $5.08 low side on TRIV, and $4.90 limit order, looks to be headed down there near term, however it may have double bottomed, or is setting up for one off it's $12.00 IPO in 2014;... with earnings call due on Aug 5, 15, could build expectations that their sales force has finally gotten traction, and could be a price catalyst into the August earnings call, thus the $6.84 Alert. Also B of A lowered their $110 price target, may be the analysts got info that the sales team has really turned the corner?

[dayneyus]

Video of the Ovation System:

Company web site and video:
http://www.trivascular.com/index.php?option=com_content&view=article&id=12&Itemid=148

[dayneyus]

Some interesting projections from Management's last Con. Call

Mike Kramer - TriVascular Technologies Inc. - CFO
On financing, so couple of things -- our first priority is to focus on growth and reaccelerating growth in the short term. Like I said earlier we are tightening our spending and making sure that we -- our incremental resources are focused on revenue generation and driving our growth priorities but we are very focused on managing the burn as well. You should expect that in the near future we'll file a shelf, we think it's just good corporate housekeeping, and we'll look at all of our financing options over the next year or so here, and we'll let you guys know when we have more to say about that.


Chris Chavez - TriVascular Technologies Inc. - President, CEO
...... Everybody is rumored to be working on something smaller. In fact others will state that it's not necessary, but it's interesting that there is a stampede to try and match us. But we are the only system in the world with 14-French system. We have the broadest IFU by far. We are the only system to my knowledge that has made public with the significant number of patients with ID date our ability to preserve and protect the aortic neck.

...So as we step back and look at the big picture we think that with the core we have today 50 plus reps we have the potential for each rep to be at $1.5 million or more[/b], it just makes it a lot of sense for us to consolidate what we have, make sure we get everybody on the right --
...
At the end of the day I think talk is cheap but data matters. What you do in clinical studies matters. What regulatory agencies ultimately approve you to use matters. And that same conference where we were both present, I think the point was made quite in a compelling way that regulatory agencies do not give you an IFU easily, that you have to earn it, you have to be able to support it and I can tell you the facts speak to themselves, our clinical data is compelling. We are the only system that can treat the range of necks -- nobody comes close to what we can do.
I will tell you that there is a lot of spin in the market. That's just part of that being in this business. But I think at the end of the day, people will look at the data. You just have to get it in front of you them, and you've just got to keep beating the drum. And I think when you go to our platform -- first of all Medtronic does not have 14-French outside diameter delivery

Bruce, let me take your first question on Alto. We're making great progress on that. We are -- as I mentioned in my opening comments we expect to be able to do first in man with Alto in the first half of next year and we've got a very well defined regulatory and clinical strategy that we think will get us to the market, we think in fast order.



system.http://files.shareholder.com/downloads/AMDA-2L5UBB/416971497x7935017x828188/8165B612-56BB-4AFF-B365-03CF05357937/TRIV-Transcript-2015-05-05T20_30.pdf

[dayneyus]

Hey what's up with bank of america price target of $110?

[stocktrademan]

$TRIV recent news/filings

bullish
bottom bounce
macd bullish divergence
rsi bullish divergence
cmf bullish divergence
stochastic bullish divergence

## source: finance.yahoo.com

Fri, 29 May 2015 20:39:38 GMT ~ TRIVASCULAR TECHNOLOGIES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements a


read full: http://biz.yahoo.com/e/150529/triv8-k.html
*********************************************************

Wed, 27 May 2015 21:09:39 GMT ~ TRIVASCULAR TECHNOLOGIES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders


read full: http://biz.yahoo.com/e/150527/triv8-k.html
*********************************************************

Fri, 15 May 2015 17:04:26 GMT ~ TRIVASCULAR TECHNOLOGIES, INC. Financials


read full: http://finance.yahoo.com/q/is?s=triv
*********************************************************

Wed, 06 May 2015 20:39:44 GMT ~ TRIVASCULAR TECHNOLOGIES, INC. Files SEC form 10-Q, Quarterly Report


read full: http://biz.yahoo.com/e/150506/triv10-q.html
*********************************************************

Tue, 05 May 2015 22:28:02 GMT ~ TriVascular reports 1Q loss


read full: http://sg.finance.yahoo.com/news/trivascular-reports-1q-loss-222802141.html
*********************************************************

$TRIV charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$TRIV company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/TRIV/company-info
Ticker: $TRIV
OTC Market Place: Not Available
CIK code: not found
Company name: TriVascular Technologies, Inc.
Incorporated In:


$TRIV share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$TRIV extra dd links

Company name: TriVascular Technologies, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/TRIV/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/TRIV/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=TRIV+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=TRIV+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=TRIV+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/TRIV/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/TRIV/news - http://finance.yahoo.com/q/h?s=TRIV+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/TRIV/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/TRIV/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/TRIV/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/TRIV/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/TRIV/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/TRIV/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/TRIV/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/TRIV/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=TRIV+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/TRIV
DTCC (dtcc.com): http://search2.dtcc.com/?q=TriVascular+Technologies%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=TriVascular+Technologies%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=TriVascular+Technologies%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/TRIV/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/TRIV
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/TRIV/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/TRIV/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/TRIV/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/TRIV/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/TRIV/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/TRIV/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/TRIV/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=TRIV&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=TRIV
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/TRIV/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=TRIV+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=TRIV+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=TRIV
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=TRIV
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=TRIV+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/TRIV/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=TRIV+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/TRIV.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=TRIV
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/TRIV/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/TRIV/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/TRIV/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/TRIV/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/TRIV
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/TRIV
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/TRIV:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=TRIV
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=TRIV



$TRIV DD Notes ~ http://www.ddnotesmaker.com/TRIV